Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of lamivudine in preparation of medicine for treating Alzheimer's disease

A technology for Alzheimer's disease and lamivudine, applied in the field of new drugs, to reduce memory and learning ability decline, reduce neuron damage, and broaden the selection field

Pending Publication Date: 2021-07-20
SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Past studies were limited to its anti-viral or anti-aging pharmacological effects, and no research h

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lamivudine in preparation of medicine for treating Alzheimer's disease
  • Application of lamivudine in preparation of medicine for treating Alzheimer's disease
  • Application of lamivudine in preparation of medicine for treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] 3TC treatment of AD model mouse SAMP8

[0032] (1) Experimental grouping, 44-week-old normal SAMR1 mice were used as the healthy control group, untreated SAMP8 mice were used as the AD model group, and SAMP8 mice fed with 3TC were used as the 3TC treatment group.

[0033] (2) Drug treatment, the healthy control group (SAMR1+Vehicle) and the AD model group (SAMP8+Vehicle) were gavaged with drinking water every day, and the treatment group (SAMP8+3TC) was gavaged with 3TC (dissolved in drinking water) , the dose is 100mg / kg, and the time is 4 weeks.

Embodiment 2

[0034] Example 2 Under the same conditions, three groups of mice were tested in the Morris water maze at the same time

[0035] (1) Orientation navigation experiment. The water maze is a circular pool (with a diameter of 120 cm and a circular platform with a diameter of 10 cm), and the water temperature is 25±1°C. Train the mice to find the platform below the water surface within one minute. If the mouse did not find the platform within 60s, it was guided to the platform and allowed to stay for 20s. Each mouse was trained five times a day, with each mouse experiment 15 minutes apart from each other. In each trial, the mouse's initial water entry location was randomly distributed within four quadrants. Record the time from entering the water to boarding the platform for each mouse for each training, which is recorded as the escape latency.

[0036] (2) Space exploration experiments. On the sixth day of testing, the platform was removed and the mice entered the water maze f...

Embodiment 3

[0041] Carry out mouse brain paraffin section and tissue staining after the experiment of embodiment 1

[0042] (1) Preparation of brain paraffin sections. After the treatment, the mice were anesthetized with 5% diethyl ether, and the brains were collected after cardiac perfusion with phosphate buffered saline (PBS) and 4% paraformaldehyde solution. Brain tissue was removed and fixed in paraformaldehyde for more than 2 days. Embed fixed brains in paraffin. Paraffin-fixed and sectioned, the paraffin mass was sectioned into 4-5 μm paraffin sections.

[0043] (2) Hematoxylin-eosin (HE) staining to analyze brain morphological changes. Paraffin sections of hippocampus tissue were taken and dewaxed and dehydrated with a series of ethanol gradients. HE staining was performed using the HE staining kit (Solarbio, Beijing, China) according to the manufacturer's instructions. After soaking in ethanol and xylene, the sections were fixed with resin and observed under an optical micros...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of novel medicines, relates to an application of lamivudine in preparation of a medicine for treating Alzheimer's disease, and provides a medicine for treating Alzheimer's disease, the main active component of which is lamivudine. A brand new thought is provided for treating the Alzheimer disease at present, the selection field for treating the Alzheimer disease is widened, and a contribution is made for further development of lamivudine.

Description

technical field [0001] The invention belongs to the field of novel drugs, relates to the application of lamivudine in the preparation of drugs for treating Alzheimer's disease, and provides a drug for treating Alzheimer's disease at the same time. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease that mostly affects people over 65 years old. AD patients experience irreversible damage to parts of the brain, impairing memory and physical function. As of 2020, there are more than 10 million AD patients in my country. The onset of AD is insidious, the course of the disease is long, and once it occurs, it is extremely difficult to reverse. The pathogenesis of AD is relatively complicated, and the research on its pathogenesis and prevention mechanism is in full swing in the medical field, but the real cause of AD is still unclear. Unfortunately, both new drug candidates and already marketed drugs for other diseases have made limited progress ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/513A61P25/28
CPCA61K31/513A61P25/28
Inventor 卢志明李明白晓卉唐琪
Owner SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com